These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 7009286)

  • 1. Effects of vasoactive intestinal polypeptide (VIP), secretin and gastrin on insulin secretion in the mouse.
    Ahrén B; Lundquist I
    Diabetologia; 1981; 20(1):54-9. PubMed ID: 7009286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of gastric inhibitory polypeptide (GIP) and cholecystokinin (CCK-8) with basal and stimulated insulin secretion in mice.
    Ahrén B; Hedner P; Lundquist I
    Acta Endocrinol (Copenh); 1983 Jan; 102(1):96-102. PubMed ID: 6130663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The entero-insular axis.
    Morgan LM
    Biochem Soc Trans; 1980 Feb; 8(1):17-9. PubMed ID: 6989667
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of vasoactive intestinal polypeptide (VIP), secretin and gastrin in the genesis of the late exocrine pancreatic hypersecretion, food intake dependent in conscious dogs.
    Huertas JR; Mañas M; Ballesta MC; Mataix FJ; Martinez-Victoria E
    Nahrung; 1993; 37(3):252-7. PubMed ID: 8361528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of two cholecystokinin variants, CCK-39 and CCK-8, on basal and stimulated insulin secretion.
    Ahrén B; Lundquist I
    Acta Diabetol Lat; 1981; 18(4):345-56. PubMed ID: 6277122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of vasoactive intestinal peptide (VIP) and secretin in gastric secretion and mucosal blood flow.
    Konturek SJ; Dembiński A; Thor P; Król R
    Pflugers Arch; 1976 Jan; 361(2):175-81. PubMed ID: 765958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of glucagon, secretin, and vasoactive intestinal polypeptide on gastric somatostatin and gastrin release from isolated perfused rat stomach.
    Chiba T; Taminato T; Kadowaki S; Abe H; Chihara K; Seino Y; Matsukura S; Fujita T
    Gastroenterology; 1980 Jul; 79(1):67-71. PubMed ID: 6103859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of gastrointestinal hormones (peptides) on insulin secretion: physiology or pharmacology?].
    Souquet JC; Riou JP; Chayvialle JA
    Journ Annu Diabetol Hotel Dieu; 1983; ():35-44. PubMed ID: 6196509
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of helospectin I on insulin and glucagon secretion in the mouse.
    Ahrén B
    Br J Pharmacol; 1991 Apr; 102(4):916-8. PubMed ID: 1855119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secretin potentiates cholinergically induced glucagon secretion in the mouse.
    Ahrén B; Lundquist I
    Acta Physiol Scand; 1986 Dec; 128(4):575-8. PubMed ID: 3811983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of vagal stimulation on pancreatic secretion and on blood levels of gastrin, cholecystokinin, secretin, vasoactive intestinal peptide, and somatostatin.
    Guzman S; Chayvialle JA; Banks WA; Rayford PL; Thompson JC
    Surgery; 1979 Aug; 86(2):329-36. PubMed ID: 462378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Peptide hormones of the digestive organs (review of the literature)].
    Germaniuk IaL
    Vrach Delo; 1983 Oct; (10):74-9. PubMed ID: 6139917
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of helodermin and VIP on insulin and glucagon secretion in the mouse.
    Ahrén B; Falck B
    Regul Pept; 1991 Jan; 32(1):1-9. PubMed ID: 2003148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of glucagon, gastric inhibitory polypeptide, pancreatic polypeptide and somatostatin on beta-adrenergically induced insulin secretion in the mouse.
    Ahrén B; Lundquist I
    Diabete Metab; 1982 Sep; 8(3):209-12. PubMed ID: 6128264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topographical distribution of the secretin- and VIP-stimulated adenylate cyclase system in the heart of five animal species.
    Chatelain P; Robberecht P; Waelbroeck M; De Neef P; Camus JC; Huu AN; Roba J; Christophe J
    Pflugers Arch; 1983 Apr; 397(2):100-5. PubMed ID: 6866728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of gastrin release and gastric secretion by gastric inhibitory polypeptide (GIP) and vasoactive intestinal polypeptide (VIP).
    Villar HV; Fender HR; Rayford PL; Bloom SR; Ramus NI; Thompson JC
    Ann Surg; 1976 Jul; 184(1):97-102. PubMed ID: 938120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuro-hormonal control of pancreatic function in man and its failure.
    Greenberg GR
    Scand J Gastroenterol Suppl; 1983; 82():101-9. PubMed ID: 6138850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of vasoactive intestinal peptide (VIP)-related peptides on cholinergic neurogenic and direct mucus secretion in ferret trachea in vitro.
    Liu YC; Khawaja AM; Rogers DF
    Br J Pharmacol; 1999 Nov; 128(6):1353-9. PubMed ID: 10578152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptors for vasoactive intestinal peptide and secretin on small intestinal epithelial cells.
    Binder HJ; Lemp GF; Gardner JD
    Am J Physiol; 1980 Mar; 238(3):G190-6. PubMed ID: 6245588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrin-releasing peptide directly releases pepsinogen from guinea pig chief cells.
    Fiorucci S; McArthur KE
    Am J Physiol; 1990 Nov; 259(5 Pt 1):G760-6. PubMed ID: 1700625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.